Pol Molina Perelló
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pol Molina Perelló has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- David Martínez Bonifacio
Centre d’Investigació de Medicaments of Institut de Recerca Sant Pau (CIM-IR Sant Pau), 08041 Barcelona, Spain
1 shared publication - Jimena Coimbra Hurtado
Centre d’Investigació de Medicaments of Institut de Recerca Sant Pau (CIM-IR Sant Pau), 08041 Barcelona, Spain
1 shared publication - Jordi Cuñé Castellana
AB Biotek Human Nutrition and Health, 08017 Barcelona, Spain
1 shared publication - Lydia Carrera Marcolin
AB Biotek Human Nutrition and Health, Spain
1 shared publication - Maite Garrido Sánchez
Centre d’Investigació de Medicaments of Institut de Recerca Sant Pau (CIM-IR Sant Pau), 08041 Barcelona, Spain
1 shared publication - Marta Castillo Ocaña
Centre d’Investigació de Medicaments of Institut de Recerca Sant Pau (CIM-IR Sant Pau), 08041 Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 3 October 2025
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (4) , 46
Evaluation of the Safety and Tolerability of Three Single Ascending Doses of Diamine Oxidase (DAO) in Healthy Volunteers: A Randomized Clinical Trial
Background/Objectives: Diamine oxidase (DAO) enzyme metabolizes dietary histamine in the gastrointestinal tract. DAO deficiency can lead to histamine intolerance (HIT), manifesting as migraines, gastrointestinal disturbances, and allergic reactions. DAO supplementation has been shown to enhance histamine breakdown, alleviating these symptoms. This randomized, double-blind, single ascending dose (SAD) Phase I clinical trial aimed to evaluate the safety and tolerability of escalating doses of DAO supplementation in healthy volunteers. Methods: Thirty participants were randomly assigned to receive single doses of 42 mg, 84 mg, or 210 mg of DAO extract (adiDAO® Veg) or placebo under fasting conditions. Vital signs, laboratory parameters, and adverse events (AEs) were monitored. Results: No serious adverse events or clinically significant changes in vital signs, ECGs, or laboratory parameters were observed. Conclusions: This trial confirms the safety and tolerability of high-dose DAO supplementation. Future studies are recommended to explore the effects of chronic high-dose administration and alternative dosage forms to improve convenience.
- 3 October 2025
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (4) , 46
Open AccessEvaluation of the Safety and Tolerability of Three Single Ascending Doses of Diamine Oxidase (DAO) in Healthy Volunteers: A Randomized Clinical Trial
Background/Objectives: Diamine oxidase (DAO) enzyme metabolizes dietary histamine in the gastrointestinal tract. DAO deficiency can lead to histamine intolerance (HIT), manifesting as migraines, gastrointestinal disturbances, and allergic reactions. DAO supplementation has been shown to enhance histamine breakdown, alleviating these symptoms. This randomized, double-blind, single ascending dose (SAD) Phase I clinical trial aimed to evaluate the safety and tolerability of escalating doses of DAO supplementation in healthy volunteers. Methods: Thirty participants were randomly assigned to receive single doses of 42 mg, 84 mg, or 210 mg of DAO extract (adiDAO® Veg) or placebo under fasting conditions. Vital signs, laboratory parameters, and adverse events (AEs) were monitored. Results: No serious adverse events or clinically significant changes in vital signs, ECGs, or laboratory parameters were observed. Conclusions: This trial confirms the safety and tolerability of high-dose DAO supplementation. Future studies are recommended to explore the effects of chronic high-dose administration and alternative dosage forms to improve convenience.